Biocompatibility studies of intravenously administered ionic-crosslinked chitosan-BSA nanoparticles as vehicles for antitumour drugs
| Autor: | Marta Benito, M. Dolores Blanco, Elena Conde Pérez, Nuria Montero, César Teijón, José M. Teijón, Rosa Olmo |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2019 |
| Předmět: |
Antioxidant
Biocompatibility medicine.medical_treatment Chemistry Pharmaceutical Farmacología Pharmaceutical Science 02 engineering and technology 030226 pharmacology & pharmacy Chitosan 03 medical and health sciences chemistry.chemical_compound Inhibitory Concentration 50 0302 clinical medicine Drug Delivery Systems In vivo Cell Line Tumor medicine Animals Humans Bovine serum albumin Rats Wistar Drug Carriers Antibiotics Antineoplastic Medicamento biology technology industry and agriculture Nanopartículas Serum Albumin Bovine Hydrogen-Ion Concentration 021001 nanoscience & nanotechnology Rats Cross-Linking Reagents chemistry Doxorubicin Delayed-Action Preparations Drug delivery biology.protein Doxorubicin Hydrochloride Nanoparticles Administration Intravenous Female 0210 nano-technology Drug carrier Nuclear chemistry Célula |
| Popis: | In this study, a new alternative of ionic crosslinked nanoparticles (NPs) based on chitosan (C) and bovine serum albumin (A; BSA) was evaluated as drug delivery system for antitumour compounds (doxorubicin hydrochloride as a model). The different responses to the pH of the medium were determined by the electrostatic interactions induced by each polymeric combination (C50/A50; C80/A20; C20/A80). NPs revealed a nanoscale size (167-392 nm) and a positive net charge (12-26 mV), modulated by doxorubicin (DOX) loading. Drug loading capacity was higher than 5.2 ± 1.8 μgDOX/mgNP (Encapsulation efficiency = 34%), and an initial burst release was followed by a sustained delivery. Cellular uptake assays confirmed the entry of NPs in three human tumor cells (MCF7, T47D and Hela), triggering antioxidant responses (superoxide dismutase, catalase, glutathione reductase and total glutathione content) in those cells. This was also consistent with the decreased in IC50 values observed after the incubation of these cells with C20/A80-DOX and C50/A50-DOX NPs (1.90-3.48 μg/mL) compared with free DOX (2.36-6.025 μg/mL). In vivo results suggested that the selected proportions of chitosan-BSA created nonhemolytic and biocompatible stable NPs at the selected dose of 20 mg/kg. Despite the different formulations, this study demonstrated that these NPs could serve as safe drug carriers in further in vivo investigations. Santander-UCM, Madrid, Spain (PR26/16-20273) 4.845 JCR (2019) Q1, 31/271 Pharmacology & Pharmacy 1.081 SJR (2019) Q1, 19/218 Pharmaceutical Science No data IDR 2019 UEM |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|